P. Donga

Comparative healthcare costs in patients with metastatic melanoma in the USA.

Recent advances have increased treatment options for, and improved clinical outcomes in, metastatic melanoma (mM). Using a large claims database, this retrospective study compared healthcare and adverse event (AE) costs in a US managed care population of mM patients initiating vemurafenib (VEM), ipilimumab (IPI), dacarbazine (DTIC), paclitaxel (PAC), or temozolomide (TMZ) from July 2009 to September 2012. Treatment episodes were identified from the start of study drugs (index date) to a switch to a different study drug, or a gap greater than 45 days (>112 days for IPI). Grade 3/4 adverse events occurring ≥5% from study drug package inserts were selected for this analysis. All-cause costs for treatment episodes and AEs were normalized as monthly costs. Generalized estimating equation models with log link and gamma distribution provided adjusted monthly treatment episode and AE costs. A total of 809 treatment episodes were identified in 541 mM patients, with a mean (SD) age of 57.5 (11.5) years. The total mean (SD) all-cause cost per treatment episode for VEM was

Symptom report and treatment experience of hypogonadal men with and without type 2 diabetes in a United States health plan.

77 687 (

Adherence and Persistence Patterns in Medication Use Among Men With Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia.

60 329), for IPI was

Economic Evaluation of Treating Skeletal-Related Events among Prostate Cancer Patients

153 062 (

Comparative treatment-related adverse event cost burden in immune thrombocytopenic purpura

134 048), for DTIC was

AB1091 Treatment Persistence with Subcutaneous Biologic Therapies in Patients with Rheumatoid Arthritis

35 243 (

AB1077 Treatment Patterns and Persistence with Subcutaneous Biologic Therapies in Patients with Ankylosing Spondylitis

33 641), for TMZ was

Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.

42 870 (

Survival of U.S. Medicare patients with advanced non-small cell lung cancer by line of therapy.

41 384), and for PAC was

Real-World Use of Systemic Anticancer Treatment by Histology and Line of Therapy in U.S. Medicare Patients With Advanced Non-Small Cell Lung Cancer

58 991 (